Literature DB >> 33318039

Unconventional Secretion of PKCδ Exerts Tumorigenic Function via Stimulation of ERK1/2 Signaling in Liver Cancer.

Kohji Yamada1, Tsunekazu Oikawa2, Ryusuke Kizawa1, Saya Motohashi1, Saishu Yoshida1, Tomotaka Kumamoto1, Chisato Saeki2, Chika Nakagawa2, Yuya Shimoyama1, Katsuhiko Aoki1, Toshiaki Tachibana3, Masayuki Saruta2, Masaya Ono4, Kiyotsugu Yoshida5.   

Abstract

Expression of human protein kinase C delta (PKCδ) protein has been linked to many types of cancers. PKCδ is known to be a multifunctional PKC family member and has been rigorously studied as an intracellular signaling molecule. Here we show that PKCδ is a secretory protein that regulates cell growth of liver cancer. Full-length PKCδ was secreted to the extracellular space in living liver cancer cells under normal cell culture conditions and in xenograft mouse models. Patients with liver cancer showed higher levels of serum PKCδ than patients with chronic hepatitis or liver cirrhosis or healthy individuals. In liver cancer cells, PKCδ secretion was executed in an endoplasmic reticulum (ER)-Golgi-independent manner, and the inactivation status of cytosolic PKCδ was required for its secretion. Furthermore, colocalization studies showed that extracellular PKCδ was anchored on the cell surface of liver cancer cells via association with glypican 3, a liver cancer-related heparan sulfate proteoglycan. Addition of exogenous PKCδ activated IGF-1 receptor (IGF1R) activation and subsequently enhanced activation of ERK1/2, which led to accelerated cell growth in liver cancer cells. Conversely, treatment with anti-PKCδ antibody attenuated activation of both IGF1R and ERK1/2 and reduced cell proliferation and spheroid formation of liver cancer cells and tumor growth in xenograft mouse models. This study demonstrates the presence of PKCδ at the extracellular space and the function of PKCδ as a growth factor and provides a rationale for the extracellular PKCδ-targeting therapy of liver cancer. SIGNIFICANCE: PKCδ secretion from liver cancer cells behaves as a humoral growth factor that contributes to cell growth via activation of proliferative signaling molecules, which may be potential diagnostic or therapeutic targets. ©2020 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33318039     DOI: 10.1158/0008-5472.CAN-20-2009

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  5 in total

1.  Extended-synaptotagmin 1 engages in unconventional protein secretion mediated via SEC22B+ vesicle pathway in liver cancer.

Authors:  Kohji Yamada; Saya Motohashi; Tsunekazu Oikawa; Naoko Tago; Rei Koizumi; Masaya Ono; Toshiaki Tachibana; Ayano Yoshida; Saishu Yoshida; Masayuki Shimoda; Masahiro Oka; Yoshihiro Yoneda; Kiyotsugu Yoshida
Journal:  Proc Natl Acad Sci U S A       Date:  2022-08-31       Impact factor: 12.779

2.  Extracellular PKCδ signals to epidermal growth factor receptor for tumor proliferation in liver cancer cells.

Authors:  Kohji Yamada; Ryusuke Kizawa; Ayano Yoshida; Rei Koizumi; Saya Motohashi; Yuya Shimoyama; Yoshito Hannya; Saishu Yoshida; Tsunekazu Oikawa; Masayuki Shimoda; Kiyotsugu Yoshida
Journal:  Cancer Sci       Date:  2022-05-12       Impact factor: 6.518

3.  Co-administration of tyrosine kinase inhibitors with rottlerin in metastatic prostate cancer cells.

Authors:  Wojciech A Cieslikowski; Tobias Haber; Slavomir Krajnak; Katharina Anic; Annette Hasenburg; René Mager; Joachim W Thüroff; Walburgis Brenner
Journal:  EXCLI J       Date:  2021-11-19       Impact factor: 4.068

4.  miR-647 inhibits hepatocellular carcinoma cell progression by targeting protein tyrosine phosphatase receptor type F.

Authors:  Xiangyang Ye; Rongxian Qiu; Xiongzhi He; Zhengting Hu; Fengfeng Zheng; Xiaogang Huang; Xuemei Xie; Feihua Chen; Hangbing Ou; Guoxian Lin
Journal:  Bioengineered       Date:  2022-01       Impact factor: 3.269

Review 5.  Multiple subcellular localizations and functions of protein kinase Cδ in liver cancer.

Authors:  Kohji Yamada; Kiyotsugu Yoshida
Journal:  World J Gastroenterol       Date:  2022-01-14       Impact factor: 5.742

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.